MedPath

Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

Completed
Conditions
Covid19
Vaccination Reaction
Registration Number
NCT05043168
Lead Sponsor
University of Giessen
Brief Summary

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

Detailed Description

The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
42
Inclusion Criteria
  • being diagnosed with COVID-19 when kidney biopsy was performed
  • history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines
Exclusion Criteria
  • Patient refuses participation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Frequency of histopathologically confirmed glomerular and tubulointerstitial diseasesKidney biopsy obtained during COVID-19 disease and up to 3 months after SARS-CoV-2 vaccination
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Clinic Giessen and Marburg - Campus Giessen

🇩🇪

Giessen, Hessen, Germany

© Copyright 2025. All Rights Reserved by MedPath